KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Non-Current Assets (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Non-Current Assets for 7 consecutive years, with $18.1 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 10.18% to $18.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $68.2 billion through Dec 2025, up 9.37% year-over-year, with the annual reading at $18.1 billion for FY2025, 10.18% up from the prior year.
  • Non-Current Assets hit $18.1 billion in Q4 2025 for Royalty Pharma, up from $17.5 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $18.1 billion in Q4 2025 to a low of $13.5 billion in Q1 2021.
  • Historically, Non-Current Assets has averaged $15.2 billion across 5 years, with a median of $14.8 billion in 2021.
  • Biggest five-year swings in Non-Current Assets: decreased 7.85% in 2023 and later increased 15.01% in 2024.
  • Year by year, Non-Current Assets stood at $14.6 billion in 2021, then fell by 2.59% to $14.3 billion in 2022, then grew by 5.96% to $15.1 billion in 2023, then grew by 8.69% to $16.4 billion in 2024, then rose by 10.18% to $18.1 billion in 2025.
  • Business Quant data shows Non-Current Assets for RPRX at $18.1 billion in Q4 2025, $17.5 billion in Q3 2025, and $16.8 billion in Q2 2025.